Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hematology 2 > Myelodyplastic Syndrome > Flashcards

Myelodyplastic Syndrome Flashcards

1
Q

TRUE/FALSE: MDS is a molecular, cytogenetic, immunological criteria, and
morphological features, according to FAB

A

FALSE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

TRUE/FALSE: It is Characterized by progressive cytopenias in PB

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

TRUE/FALSE: Patients with MDS have an increased risk to transform to Acute Lymphocytic Leukemia (ALL)

A

FALSE - Acute Myeloid Leukemia (AML)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The abnormalities in MDs is classified as?

A

Refractory Anemia, Smoldering Leukemia, Oligoblastic Leukemia, Preleukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

TRUE/FALSE: MDs is classified as molecular, cytogenetic, immunological criteria, and morphological features, according to FAB.

A

FALSE by WHO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Median age of diagnosis in MDs patient?

A

76 years old

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

MDs has progressive cytopenia’s in PB, that reflects on all cell lines such as:

A

Myeloid, Lymphoid, Megakaryocytic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MDs has phenotypically ___ hematopoietic stem cell; ____ frequency in bone marrow with one or more somatic mutations.

A

normal; low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TRUE/FALSE: People may manifest the somatic mutation but may not manifest MDs.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MDs is described as a ____ hematopoietic disorder.

A

clonal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CHIP

A

Clonal Hematopoiesis of indeterminate potential

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

TRUE/FALSE: 10% individuals older than 90 have CHIP.

A

FALSE - Approximately 10% of individuals who are older than 65
and nearly 20% older than 90 have CHIP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

The complex interaction causing CHIP are:

A

Somatic mutation, epigenetic modification, BM microenvironment, and environmental stimuli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Conditions/Predisposition to MDs are:

A

Fanconi’s Anemia
Diamond Black Fan Anemia
Shwachman-Diamond Syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Characterizations of MDs:

A

Progressive cytopenias but normal cellular BM
Dyspoiesis in one or more cell lines
Disruption of apoptosis due to ineffective hematopoiesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Modified T/F: MDs can transform apparently to leukemia; This causes an increase in apoptosis

A

1st Statement: True
2nd Statement: False - decrease apoptosis, as it allow increase neoplastic cell survival and the expansion of abnormal growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

The pattern of abnormalities in MDs is referred as:

A

Refractory Anemia; Smoldering Leukemia; Oligoblastic Leukemia; Preleukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

T/F: Oftenly affects individuals younger than age 50 unless
preceded by chemotherapy or radiation used in the
treatment of another malignancy.

A

FALSE -rarely

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

The cell origin of MDS is _____

A

Myeloid progenitor wherein patients with MDs develop lymphoid malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

T/F: Healthy patients may have clonal hematopoiesis but do

develop a hematologic disorder.

A

FALSE - do not develop hematologic disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Known to be a precursor state for many hematologic disorders, including MDS

A 
clonal hematopoiesis of
indeterminate potential (CHIP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

T/F: The rate of Transformation of CHIP is high

A

FALSE - low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the primary MDS

A

De novo mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Effects of some leukemogenic chemotherapies and therapeutic

radiation are known to cause

A

Genetic mutations and Cellular

disruptions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

The median onset of therapy-related MDS (t-MDS)

A

Usually 4 to 7 years after therapy was initiated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

This is an aggressive and may evolve quickly into AML

A

t-MDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

The Apoptosis regulates the cell population by ________ cell survival. Yet, in early disease, apoptosis is _______ where peripheral blood cytopenia are evident. The progression of MDs toward leukemia is apparent, apoptosis is _______ where it allows _______ neoplastic cell survival.

A

decreasing; increase; decreased; increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Defective development of RBC

A

DYSERYTHROPOIESIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

The most common morphologic finding in dyserythropoiesis is __________.

A

presence of oval macrocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Findings in Dyserythropoiesis
_______ microcytes
_______ macrocytes
_______ Vitamin B12 and Folate values

A

Presence of oval macrocytes
Normal Vitamin B12 and folate values
Hypochromic microcytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Erythrocyte undergoing abnormal development indicates:

A 
Poikilocytosis
Basophilic stippling
Howell-Jolly bodies
Siderocytes/Ring sideroblast
Megaloblastoid
Erythrocytic Hyperplasia/ Hypoplasia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Dyserythropoiesis morphological findings in NUCLEUS include:

A 
More than one nucleus or abnormal (Bilobed)
nuclear shapes
Nuclear fragments
Internuclear bridging
Nuclear budding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Dyserythropoiesis morphological findings in CYTOPLASM include:

A

Basophilic stippling

Heterogeneous staining

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Morphologic Evidence of Dyserthropoiesis:
______ macrocytes
______ microcytes
______ red blood cell (RBC) population
RBC precursors with ____ than ____ nucleus
RBC precursors with ______ nuclear shapes
RBC precursors with ______ cytoplasmic staining
______ sideroblasts

A

Oval macrocytes
Hypchromic microcytes
Dimorphic red blood cell (RBC) population
RBC precursors with more than one nucleus
RBC precursors with abnormal nuclear shapes
RBC precursors with uneven cytoplasmic staining
Ring sideroblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Dysmyelopoiesis: Its peripheral blood findings
_______ in the cytoplasm (Basophilia or Basopenia)
_______ granules of neutrophil cytoplasms
_______ granules (Hypogranulation/ Hypergranulation)
_______ bands
_______ nuclear features (hypo/hyper or both; with or without nuclear rings)

A 
Persistence of basophilia in the cytoplasm of mature white
blood cells
○ Indicative of nuclear-cytoplasmic asynchrony
● Abnormal granulation of neutrophil cytoplasms
○ Larger granules
○ Hypogranulation/Agranulation
● Agranular bands
○ May be misidentified as monocytes
● Abnormal nuclear features
○ Hyposegmentation
○ Hypersegmentation
○ Presence of nuclear rings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

In dysplastic marrows, ______ hyperplasia is commonly found

A

Monocytic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q 
Morphologic findings of DYSMYELOPOIESIS:
Persistent \_\_\_\_\_\_ cytoplasm
\_\_\_\_\_\_\_\_ granulation
\_\_\_\_\_\_\_\_ nuclear shapes
\_\_\_\_\_\_\_\_ cytoplasmic staining
A

Persistent basophilic cytoplasm
Abnormal granulation
Abnormal nuclear shapes
Uneven cytoplasmic staining

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

A MDs disorder wherein platelets exhbit dyspoietic morphology in the peripheral
blood

A

DYSMEGAKARYOPOIESIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

The platelets in Dysmegakaryopoiesis described as _________

A

Larged fused granules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

In Dysmegakaryopoiesis, _____ (micro/macro) megakaryocytes circulates in the blood

A

Micromegakaryocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q 
The abnormal morphology in megakaryocytic BONE MARROW exhibit:
\_\_\_\_\_\_\_\_\_\_\_ megakaryocytes
Micromega \_\_\_\_\_\_\_
Micromega \_\_\_\_\_\_\_
Nuclei in cells may be:
■\_\_\_\_\_\_\_ (how many lobes)
■ \_\_\_\_\_\_\_ separated nuclei
A 
Large mononuclear megakaryocytes
○ Micromegakaryocyte
○ Micromegakaryoblasts
○ Nuclei in cells may be:
■ Bilobed
■ Multiple separated nuclei
42
Q

The morphologic evidences found in DYSMEGAKARYOPOIESIS:
_______ platelets
Platelets with ______ granulation
Circulating ____megakaryocytes (micro/macro)
Large ________ megakaryocytes
● Micromegakaryocytes or micromegakaryoblasts or both
● Abnormal nuclear shapes in the
megakaryoctes/megakaryoblasts

A 
Giant platelets
● Platelets with abnormal granulation
● Circulating micromegakaryocytes
● Large mononuclear megakaryocytes
● Micromegakaryocytes or micromegakaryoblasts or both
● Abnormal nuclear shapes in the
megakaryoctes/megakaryoblasts
43
Q 
Abnormal cellular function: Increased/Decreased/Normal
\_\_\_\_\_ Myeloperoxidase
\_\_\_\_\_ Alkaline Phosphate
\_\_\_\_\_ Chemotaxis
\_\_\_\_\_ Adhesion
\_\_\_\_\_ Phagocytosis
\_\_\_\_\_ Platelet Count
\_\_\_\_\_ RBC life span
A

Decreased levels of myeloperoxidase and alkaline
phosphatase may be found.

WBC
● Decreased adhesion, deficient
phagocytosis
● Decreased chemotaxis, impaired
microbicidal capacity

RBC
● Shortened life span
● Decrease response to EPO causing anemia

Platelet
● Increased bleeding despite normal platelet count

44
Q

There should be atleast ____ % blasts in the BM to diagnose ACUTE LEUKEMIA

A

30

45
Q

The five classification of MDs according to FAB are:

A
  1. Refractory anemia
  2. Refractory anemia with ring sideroblasts (RARS)
  3. Refractory anemia with excess blasts (RAEB)
  4. Chronic myelomonocytic leukemia
  5. Refractory anemia with excess blasts in transformation
    (RAEB-t)
46
Q

The threshold for dysplasia in MDs patient, is defined as ____ % dysplastic cells in any hematopoietic lineage.

A

10

47
Q

The percentage of blasts required for diagnosis of acute

leukemia has decreased to ____%.

A

20

48
Q

Classification of Myelodysplastic syndromes, according to WHO are:

A

● MDS with single lineage dysplasia (MDS-SLD)
● MDS with ring sideroblasts (MDS-RS)
○ MDS-RS and single lineage dysplasia
○ MDS-RS and multilineage dysplasia
● MDS with multilineage dysplasia
● MDS with excess blasts (MDS-EB)
○ MDS-EB-1
○ MDS-EB-2
● Myelodysplastic syndrome with isolated del(5q)
● Myelodysplastic syndrome, unclassifiable
● Childhood myelodysplastic syndrome
○ Refractory cytopenia of childhood (provisional)

49
Q

A refractory cytopenia with

unilineage dysplasia

A

MDS with single lineage dysplasia

MDS-SLD

50
Q

These symptoms related to cytopenia, demonstrate ______

○ fatigue or shortness of breath if anemia is present
○ increased infections from neutropenia
○ petechiae, bruising, or bleeding from thrombocytopenia

A

MDS with single lineage dysplasia

MDS-SLD

51
Q

In MDs cases, < __ % in peripheral blood;

A

In MDS cases, less than 1% blasts in the peripheral blood and less than 5% blasts in the bone marrow.

52
Q

The median survival of MDS with single lineage dysplasia

(MDS-SLD) is ____ years

A

5

53
Q

Formerly known as refractory cytopenia with multilineage

dysplasia

A

MDS with multiple lineage dysplasia

54
Q

One or more cytopenias, dysplasia in two or more myeloid

cell lines.

A

MDS with multiple lineage dysplasia

55
Q

The median survival of MDS with multiple lineage dysplasia is ____ years.

A

31 to 38 months

56
Q

The risk of transformation to AML of MDS with single lineage dysplasia
(MDS-SLD) ___% to ___%

A

2% to 12% risk of

transformation to AML

57
Q

The risk of transformation to AML of MDS with multiple lineage dysplasia ___% to ___%

A

with a 10% to

12% risk of transformation to AML within 5 years.

58
Q

MDS with ring sideroblasts has mutations in the spliceosome gene ______

A

SF3B1

59
Q

This MDS classification contains A ring sideroblast is an erythroid precursor containing at least
five iron granules per cell, and these iron-containing
mitochondria must circle at least one-third of the nucleus.

A

MDS with ring sideroblasts

60
Q

T/F: If a mutation in SF3B1 is identified, only 15% of nucleated
erythroid cells must be ring sideroblasts. If a mutation in SF3B1 is not detected, 5% of the bone
marrow erythroid precursors must be ring sideroblasts to
make this diagnosis.
1st Statement:___; 2nd Statement

A

Both statements - FALSE
If a mutation in SF3B1 is identified, only 5% of nucleated
erythroid cells must be ring sideroblasts. If a mutation in SF3B1 is not detected, 15% of the bone
marrow erythroid precursors must be ring sideroblasts to
make this diagnosis.

61
Q

Patients with this kind of MDs have anemia and dyserythropoiesis

A

MDS with Ring sideroblasts

62
Q

The peripheral blood of Patients with MD-RS demonstrates dimorphic population, these are:

A

hypochromic cells and

normochromic cells.

63
Q

MDS-RS with single lineage dysplasia, median age is ____ yrs old

A

71

64
Q

T/F: MDS-RS with single dysplasia has a worse prognosis

than MDS with multilineage lineage dysplasia

A

FALSE - MDS-RS with multilineage dysplasia has a worse prognosis
than MDS with single lineage dysplasia

65
Q

Trilineage cytopenias, as well as significant

dysmyelopoiesis, dysmegakaryopoiesis, or both

A

MDS with excess blasts

66
Q

MDS with Excess Blasts? What subtype define:

5% to 9% blasts in the bone marrow or 2% to 4% blasts in the peripheral blood

A

MDS-EB1

67
Q

MDS with Excess Blasts? What subtype define:
10% to 19% blasts in the bone marrow and
5% to 19% blasts in the peripheral blood

A

MDS-EB-2

68
Q

This subtype of MDS-Blast contais Auer Rods?

A

MDS-EB-2

69
Q

the only MDS WHO recognized MDS with a defining cytogenetic abnormality

A

MDS with Isolated Del (5q) (5q-SYNDROME)

70
Q

T/F: MDS with Isolated Del (5q) (5q-SYNDROME) affect predominantly ______ (man/women)

A

Women

71
Q

MDS with Isolated Del (5q) (5q-SYNDROME), median survival of patient ranges from _____ to ____ months

A

54 to 146 months

72
Q

Treatment for MDS with Isolated Del (5q) (5q-SYNDROME) which has proven to be effective in patients

A

Revlimid - Thalidomide Analog Lenalidomide

73
Q

A MDS that initially lack specific changes

A

MDS, Unclassifiable (MDS-U)

74
Q

A type of MDS wherein:
Blasts are ____ in PB in MDS with Isolated Del (5q)
Blasts are ____ in PB in MDS unclassifiable

A

<1 %; 1%

75
Q

The diagnosis for patients that demonstrates:
○ 1% peripheral blood blasts,
○ single linage dysplasia and pancytopenia, or an
○ MDS-defining cytogenetic abnormality

A

MDS, Unclassifiable (MDS-U)

76
Q

A De novo MDS in children occurs rarely. This kind of MDS is known as _____

A

Childhood myelodysplastic Syndromes

77
Q

Gene mutations occurs in De novo MDS are

A

specific inherited gene mutations such as RUNX1,

SOS1, GATA2, ANKRD26,

78
Q

Classifications of Myelodysplastic or Myeloproliferative neoplasms are:

A

○ Chronic myelomonocytic leukemia (CMML);
○ Atypical chronic myeloid leukemia (aCML);
○ Juvenile myelomonocytic leukemia (JMML);
○ Refractory anemia with ring sideroblasts and
thrombocytosis (MDS/MPN-RS-T);
○ MDS/MPN, unclassifiable

79
Q

Absence of BCR or ABL1

A

CHRONIC MYELOMONOCYTIC LEUKEMIA

80
Q

Absence of rearrangement of PDGFRA, PDGFRB, FGFR1,

PCM1-JAK2

A

CHRONIC MYELOMONOCYTIC LEUKEMIA

81
Q

Absence of rearrangements in CHRONIC MYELOMONOCYTIC LEUKEMIA include:

A

PDGFRA,

PDGFRB, FGFR1, or PCM1-JAK2

82
Q

Mutation in TET2, SRSF2, ASXL1, RUNX1

A

CHRONIC MYELOMONOCYTIC LEUKEMIA

83
Q

BCR/ABL1 is negative

A

ATYPICAL CHRONIC MYELOID LEUKEMIA,

BCR/ABL1 NEGATIVE

84
Q

characterized by leukocytosis with morphologically

dysplastic neutrophils and their precursors.

A

ATYPICAL CHRONIC MYELOID LEUKEMIA,

85
Q

ATYPICAL CHRONIC MYELOID LEUKEMIA, dyspoiesis is seen in all cell lines, but it is most remarkable in ________ (type of WBC). It exhibits _______, ________, and, ________.

A

Neutrophils; Pelger-Huët-like cells; hypogranularity; and

bizarre segmentation.

86
Q

This type of MDS and MPN has a poor prognosis for patients with _____, due to progress to AML or succumb to bone marrow
failure

A

ATYPICAL CHRONIC MYELOID LEUKEMIA,

87
Q

It is a clonal disorder characterized by proliferation of the granulocytic and monocytic cell lines and affects children from 1 month to 14 years of age

A

JUVENILE MYELOMONOCYTIC LEUKEMIA

88
Q

JUVENILE MYELOMONOCYTIC LEUKEMIA have somatic or germline mutations that activate the _________ pathway

A

RAS/MAPK

89
Q

A type of MDS/MPN that has a strong association with congenital disorders such
as Noonan syndrome and neurofibromatosis type 1.62

A

JUVENILE MYELOMONOCYTIC LEUKEMIA

90
Q

it is often associated with
mutations in SF3B1 and JAK2 V617F provided rational for
the nature of the disease

A

MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM

WITH RING SIDEROBLASTS AND THROMBOCYTOSIS

91
Q 
This type of MDS/MPN that presents with:
○ Anemia
○ 15% or more ring sideroblasts
○ Thrombocytosis
○ atypical megakaryocytes
○ and 1% or less of blasts in the peripheral blood and 5%
or less of blasts in the bone marrow
A

MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM

WITH RING SIDEROBLASTS AND THROMBOCYTOSIS

91
Q 
This type of MDS/MPN that presents with:
○ Anemia
○ 15% or more ring sideroblasts
○ Thrombocytosis
○ atypical megakaryocytes
○ and 1% or less of blasts in the peripheral blood and 5%
or less of blasts in the bone marrow
A

MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM

WITH RING SIDEROBLASTS AND THROMBOCYTOSIS

92
Q

MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE

A

is used for cases
that meet the criteria for MDS/MPN but do not fit into one
of the aforementioned subcategories

93
Q

A type of cytogenetic diagnosis that has a major effect on prognosis in MDS patients

A

Karyotype

94
Q

T/F: Cytogenetic abnormality is non-specific to a subtype of

MDS

A

FALSE

95
Q

Most common abnormalities of chromosome involve in MDS are:

A

chromosomes 5, 7,

8, 18, 20, and 13

96
Q

The most common single abnormalities in MDS besides del (5q) are

A

trisomy 8 and monosomy 7, 12p–, iso 17, –21, and loss of the

Y chromosome

97
Q

The mutations affect five major groups of genes:

A 
○ RNA splicing
○ DNA methylation
○ activated cell signaling
○ myeloid transcription factors
○ chromatin modifiers
98
Q

The most favorable prognosis of mutation in MDS is ______: while _____ confers negative prognosis and predict a higher risk of transformation to AML

A

SF3B1; TP53

99
Q

Mutations that play important roles in altering CpG island

methylation _______; while ______ play important roles in altering histone methylation

A

TET2; ASXL1

100
Q

The most widely used prognostic

scoring models for MDS

A

IPSS and IPSS-R

101
Q

prescribed for

patients with low-risk MDS.

A

Lenalidomide and azanucleosides

Hematology 2 (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions